Short answer
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Aclaris financial results for the quarter ended September 30, 2026.
Aclaris Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Aclaris financial results for the quarter ended September 30, 2026
- Nine-month results through September 30, 2026 also announced
- Investor-relevant figures and management commentary are in the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.5M versus $3.3M, while net loss widened to $18.5M from $14.6M
- Cash, equivalents and marketable securities $204.6M, with October financing adding $50.0M gross proceeds
- Cash runway expected through first half of 2029, reducing near-term financing risk but reflecting substantial development spending
- ATI-052 Phase 1b results: 45% placebo-adjusted EASI improvement and 78% placebo-adjusted EASI-50 at week 8
- Key catalysts: bosakitug Phase 2 AD results and modzatinib Phase 2b lichen planus trial expected in Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aclaris Therapeutics, Inc. 8-K filings
Get the next ACRS 8-K as it lands
Follow ACRS for push alerts, or ask the research agent what this filing means.